Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI314 in Patients With Mild to Moderate COVID-19
NCT05172141Phase 2Terminated
- Sponsor
- Innovent Biologics
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing IBI314 with Placebo (2 arms). Primary endpoints: Number of treatment related Adverse Events at 29 days and Virologic efficacy Evaluation at Day 7. Started Dec 2021; status: terminated.
02
Drugs
IBI314
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05172141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05172141.